
    
      An eight week, randomized, placebo controlled trial to assess subjective changes in mood and
      anxiety symptoms from baseline to after MET-2 treatment in participants with depression,
      using MADRS, Hamilton Anxiety Rating Scale (HAM-A), and other mood/anxiety scales and to
      demonstrate a significantly higher proportion of responders in patient who were randomized to
      receive the active study drug compared to patients who were randomized to receive placebo.
    
  